HealthCare Royalty Partners (HCR) announced the closing of its latest fund, HealthCare Royalty Partners IV, with $1.83 billion, with new investors representing several of the world’s leading pensions, sovereign wealth funds, financial institutions, foundations and family offices.
The Stamford, Conn.-based $5.5 billion private debt firm uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets.Fund IV, like its predecessor funds will seed to provide returns that are non-correlated to the broader equity or credit markets. Since 2003, the firm has invested more than $3 billion in commercial . . .
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators